6 completed, 1 terminated. 2 Not applicable, 2 Phase 3, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Orexo AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder OXD01 digital therapy, Standard of Care - Opioid-use Disorder | Not applicable | Completed | Orexo AB | 437 | 2021-06-30 | 2025-06-27 |
| Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy AiCure monitoring and intervention - Opiate Addiction, Medication Non-adherence | Not applicable | Completed | AiCure | 9 | 2016-08-01 | 2017-09-12 |
| Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults BNX sublingual tablets, BNX sublingual film, Buprenorphine - Opioid Dependence, on Agonist Therapy | Phase 3 | Completed | Orexo AB | 759 | 2013-08-01 | 2017-05-10 |
| Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Higher bioavailability BNX sublingual tablets - Opioid Dependence, on Agonist Therapy | Phase 4 | Completed | Orexo AB | 668 | 2013-07-01 | 2015-10-28 |
| Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence Buprenorphine/naloxone sublingual tablets, Buprenorphine - Opioid-Related Disorders, Opiate Dependence | Phase 3 | Completed | Orexo AB | 313 | 2013-06-01 | 2017-05-10 |
| Conversion From Fast Acting Oral Opioids to AbstralĀ® SL fentanyl - Pain | Phase 4 | Terminated | Orexo AB | 8 | 2011-02-21 | 2017-04-05 |
| Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis BLX-028914, placebo - Allergic Rhinitis | Phase 2 | Completed | Dart NeuroScience, LLC | 36 | 2008-09-01 | 2013-03-13 |
Opioid-Related Disorders (5) · Behavior, Addictive (1) · Directly Observed Therapy (1) · Medication Adherence (1) · Pain (1) · Patient Compliance (1) · Rhinitis, Allergic (1)
Buprenorphine (3) · Buprenorphine, Naloxone Drug Combination (3) · Fentanyl (1) · Methods (1) · Standard of Care (1)
United States (5) · Sweden (2)
Adam Hanina, MBA, MPhil (1) · Alain Litwin, MD (1) · Anders Pettersson, MD, PhD (1) · David Capano, PharmD (1) · Erik Gunderson (1) · Kent Hoffman (1) · Lennart Greiff, MD, PhD (1) · Lynn Webster (1)